Daan Gene (SHE:002030) received approval from the Chinese drug administration for its novel coronavirus 2019-nCoV nucleic acid detection kit (fluorescence PCR method), according to a Shenzhen Stock Exchange disclosure on Tuesday.
The certificate is valid until Dec. 29, 2029, the Chinese medical laboratory company said.
Daan Gene's company fell less than 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.